Olivier FARDEL GROUP SITE

Olivier Fardel received his PharmD in 1986 and his PhD on the “Expression and regulation of P-glycoprotein in normal and cancerous hepatocytes” in 1993 at the University of Rennes (France). He is currently full professor at the Faculty of Pharmaceutical and Biological Sciences of Rennes (University of Rennes 1). He leads a research team at the Research Institute for Environmental and Occupational Health (IRSET), a joint project between the French national agency for medical research (INSERM), Rennes 1 University and EHESP School of Public Health. His research activities notably concern cellular and molecular regulation of drug transporter expression and activity in hepatocytes and functional consequences for hepatobiliary disposition of drugs and environmental chemical contaminants. He published more than 150 original and review articles in peer-refereed scientific journals and scientific books.

  • Eur J Drug Metab Pharmacokinet. 2021;46:625-635. Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) activity by Tyrosine Kinase Inhibitors. Jouan E, Moreau A, Bruyere A, Alim K, Denizot C, Parmentier Y, Fardel O. PubMed
  • Biopharm Drug Dispos. 2021;42:393-398. Comparative in silico prediction of P-glycoprotein-mediated transport for 2010-2020 US FDA-approved drugs using six Web-tools. Guéniche N, Huguet A, Bruyere A, Habauzit D, Le Hégarat L, Fardel O. PubMed
  • Fundam Clin Pharmacol. 2021;35:919-929. Inhibition of organic cation transporter 3 activity by tyrosine kinase inhibitors. Alim K, Moreau A, Bruyère A, Jouan E, Denizot C, Nies AT, Parmentier Y, Fardel O. PubMed
  • Xenobiotica. 2021;51:467-478. Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters. Bruyère A, Le Vée M, Jouan E, Molez S, Nies AT, Fardel O. PubMed
  • Expert Opin Drug Metab Toxicol. 2021;17:259-271. Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. Alim K, Bruyère A, Lescoat A, Jouan E, Lecureur V, Le Vée M, Fardel O. PubMed
  • Xenobiotica. 2020 Jun 4:1-13. Differential interactions of carbamate pesticides with drug transporters. Guéniche N, Bruyere A, Ringeval M, Jouan E, Huguet A, Le Hégarat L, Fardel O. PubMed
  • Int Immunopharmacol. 2020 Jun;83:106439. Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells. Le Vée M, Bruyère A, Jouan E, Fardel O. Int Immunopharmacol. 2020;83:106439. PubMed
  • Fundam Clin Pharmacol. 2020;In press. Differential interactions of the β-lactam cloxacillin with human renal organic anion transporters (OATs). Lalanne S, Le Vée M, Lemaitre F, Le Corre P, Verdier MC, Fardel O. PubMed
  • Inflamm Res. 2020;69:51-62. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes. Febvre-James M, Lecureur V, Fardel O. PubMed
  • Pest Manag Sci. 2020;76:18-25. Implication of human drug transporters to toxicokinetics and toxicity of pesticides. Guéniche N, Bruyere A, Le Vée M, Fardel O. PubMed
  • J Biochem Mol Toxicol. 2019;33:e22379. Neonicotinoid pesticides poorly interact with human drug transporters. Le Vée M, Bacle A, Bruyere A, Fardel O. PubMed
  • Toxicol In Vitro. 2019;58:60-68. Induction of multidrug resistance-associated protein 3 expression by diesel exhaust particle extract in human bronchial epithelial BEAS-2B cells. Le Vée M, Bacle A, Jouan E, Lecureur V, Potin S, Fardel O. PubMed
  • Environ Int. 2019;126:659-671. Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives. Clerbaux LA, Paini A, Lumen A, Osman-Ponchet H, Worth AP, Fardel O. PubMed
  • Pharmaceutics. 2018;10. pii: E246. mRNA expression and activity of Nucleoside Transporters in human hepatoma HepaRG cells. Mayati A, Moreau A, Jouan E, Febvre-James M, Denizot C, Parmentier Y, Fardel O. PubMed
  • Sci Rep. 2018;8:16115. Functional polarization of human hepatoma HepaRG cells in response to forskolin. Mayati A, Moreau A, Le Vée M, Bruyère A, Jouan E, Denizot C, Parmentier Y, Fardel O. PubMed
  • Toxicol In Vitro. 2019;54:10-22. Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines. Sayyed K, Camillerapp C, Le Vée M, Bruyère A, Nies AT, Abdel-Razzak Z, Fardel O. PubMed
  • Eur J Drug Metab Pharmacokinet. 2019;44:13-30. Evaluation of drug biliary excretion using sandwich-cultured human hepatocytes. Fardel O, Moreau A, Le Vée M, Denizot C, Parmentier Y. PubMed
  • Expert Opin Drug Metab Toxicol. 2018;14:739-752. Interactions of pesticides with membrane drug transporters: implications for toxicokinetics and toxicity. Chedik L, Bruyere A, Bacle A, Potin S, Le Vée M, Fardel O. PubMed
  • Eur J Pharm Sci. 2018;121:85-94. New insights in the in vitro characterisation and molecular modelling of the P-glycoprotein inhibitory promiscuity. Bocci G, Moreau A, Vayer P, Denizot C, Fardel O, Parmentier Y. PubMed
  • Xenobiotica. 2018;6:1-12. Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters. Chedik L, Bruyere A, Fardel O. PubMed
  • Drug Metab Dispos. 2018;46:131-140. The JAK1/2 inhibitor Ruxolitinib reverses interleukin-6-mediated suppression of drug-detoxifying proteins in cultured human hepatocytes. Febvre-James M, Bruyère A, Le Vée M, Fardel O. PubMed
  • Toxicol In Vitro. 2017;44:27-35. Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Sayyed K, Le Vee M, Abdel-Razzak Z, Fardel O. PubMed
  • Eur J Pharm Sci. 2017;106:302-312. β2-adrenergic receptor-mediated in vitro regulation of human hepatic drug transporter expression by epinephrine. Mayati A, Moreau A, Denizot C, Stieger B, Parmentier Y, Fardel O. PubMed
  • Int J Mol Sci. 2017;18. pii: E764. Protein Kinases C-mediated regulations of drug transporter activity, localization and expression. Mayati A, Moreau A, Le Vée M, Stieger B, Denizot C, Parmentier Y, Fardel O. PubMed
  • Eur J Drug Metab Pharmacokinet. 2017; in press. Effect of Gevokizumab on Interleukin-1β-mediated cytochrome P450 3A4 and drug transporter repression in cultured human hepatocytes. Moreau A, Le Vée M, Jouan E, Denizot C, Parmentier Y, Fardel O. PubMed
  • PLoS One. 2017;12:e0169480. Inhibition of human drug transporter activities by the pyrethroid pesticides Allethrin and Tetramethrin. Chedik L, Bruyere A, Le Vee M, Stieger B, Denizot C, Parmentier Y, Potin S, Fardel O. PubMed
  • Toxicol In Vitro. 2017;40:34-44. Inhibition of SLC drug transporter activities by environmental bisphenols. Bruyere A, Hubert C, Le Vee M, Chedik L, Sayyed K, Stieger B, Denizot C, Parmentier Y, Fardel O. PubMed
  • Pharmaceutics. 2016;9: E3. Drug transporter expression and activity in human hepatoma HuH-7 cells. Jouan E, Le Vée M, Denizot C, Parmentier Y, Fardel O. PubMed
  • Pharmaceutics. 2016;8: E12.  Evaluation of P-Glycoprotein inhibitory potential using a Rhodamine 123 accumulation assay. Jouan E, Le Vée M, Mayati A, Denizot C, Parmentier Y, Fardel O. PubMed
  • Toxicology. 2016;363-364:58-71. Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Sayyed K, Vee ML, Abdel-Razzak Z, Jouan E, Stieger B, Denizot C, Parmentier Y, Fardel O. In the present study, the authors demonstrate that cigarette smoke condensate (CSC) alters the activity and expression of hepatic drug transporters, which are recognized as major actors of hepatobiliary elimination of drugs. PubMed
  • PLoS One. 2015;10:e0144667. Protein kinase C-independent inhibition of Organic Cation Transporter 1 activity by the bisindolylmaleimide Ro 31-8220. Mayati A, Bruyere A, Moreau A, Jouan E, Denizot C, Parmentier Y, Fardel O. PubMed
  • Biochem Pharmacol. 2015;98:703-17. Protein kinase C-dependent regulation of human hepatic drug transporter expression. Mayati A, Le Vee M, Moreau A, Jouan E, Bucher S, Stieger B, Denizot C, Parmentier Y, Fardel O. PubMed
  • Methods Mol Biol. 2015;1250:287-302. Analysis of sinusoidal drug uptake transporter activities in primary human hepatocytes. Le Vée M, Jouan E, Denizot C, Parmentier Y, Fardel O. PubMed
  • Expert Opin Drug Metab Toxicol. 2015;11:1233-51. Nature and uses of fluorescent dyes for drug transporter studies. Fardel O, Le Vee M, Jouan E, Denizot C, Parmentier Y. PubMed
  • Toxicol In Vitro. 2015;29:938-46. Polarized location of SLC and ABC drug transporters in monolayer-cultured human hepatocytes. Le Vee M, Jouan E, Noel G, Stieger B, Fardel O. PubMed
  • PLoS One. 2015;10:e0121232. Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract. Le Vee M, Jouan E, Stieger B, Lecureur V, Fardel O. PubMed
  • Virology. 2015;481:34-42. Interleukin 6 inhibits HBV entry through NTCP down regulation. Bouezzedine F, Fardel O, Gripon P. PubMed
  • J Biochem Mol Toxicol. 2014;28:119-28. Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. Bucher S, Le Vee M, Jouan E, Fardel O. PubMed
  • Toxicol In Vitro. 2013;27:1979-86. Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells. Le Vee M, Noel G, Jouan E, Stieger B, Fardel O. PubMed
  • Eur J Pharm Sci. 2013;49:39-50. Functional expression and regulation of drug transporters in monolayer- and sandwich-cultured mouse hepatocytes. Noel G, Le Vee M, Moreau A, Stieger B, Parmentier Y, Fardel O. PubMed
  • Eur J Pharm Sci. 2013;48:767-74. Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes. Le Vee M, Jouan E, Stieger B, Fardel O. PubMed
  • Fundam Clin Pharmacol. 2014;28:65-77. The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2. Jouan E, Le Vee M, Denizot C, Da Violante G, Fardel O. PubMed
  • Expert Opin Drug Metab Toxicol. 2012;8:29-46. Environmental chemicals as substrates, inhibitors or inducers of drug transporters: implication for toxicokinetics, toxicity and pharmacokinetics. Fardel O, Kolasa E, Le Vee M. PubMed
  • Biochem Pharmacol. 2011;82:304-11. Regulation of drug transporter expression by oncostatin M in human hepatocytes. Le Vee M, Jouan E, Stieger B, Lecureur V, Fardel O. PubMed
  • Fundam Clin Pharmacol. 2011;25:99-103. Regulation of drug transporter mRNA expression by interferon-γ in primary human hepatocytes. Le Vee M, Jouan E, Moreau A, Fardel O. PubMed
  • Expert Opin Drug Metab Toxicol. 2009;5:1469-81. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Fardel O, Le Vée M. PubMed
  • Drug Metab Dispos. 2009;37:2228-35. Differential regulation of drug transporter expression by hepatocyte growth factor in primary human hepatocytes. Le Vee M, Lecureur V, Moreau A, Stieger B, Fardel O. PubMed
  • Drug Metab Dispos. 2009;37:685-93. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Le Vee M, Lecureur V, Stieger B, Fardel O. PubMed
  • Drug Metab Dispos. 2008;36:217-22. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Le Vee M, Gripon P, Stieger B, Fardel O. PubMed
  • Drug Metab Dispos. 2006;34:1756-63. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. PubMed

PubMed

Rennes, France

FARDEL Olivier.jpg

Last update: October 2021